undamentalytics Newsletter
Sign in

Mirum Pharmaceuticals, Inc. cash flow statement

In fiscal 2025, Mirum Pharmaceuticals, Inc.'s operations generated $55.8m of cash; it spent $954,000 on capital projects, leaving free cash flow of $54.9m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−89−133−120−711056−227
Depreciation and amortisation01311242426
Stock-based pay132327354871104
Capital spending0000111
Free cash flow−89−133−120−71955−229
Free cash flow after stock pay−102−156−147−106−39−17−333
Shares issued—0211400—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: MIRM vs TARSARWR vs MIRMHCM vs MIRMMIRM vs NRIX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Mirum Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Mirum Pharmaceuticals, Inc.